🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

New OncoKB™ release people! +14 new genes including oncogenes CDH2 & CDH4 that are members of cadherin family Also quizartinib in FLT3-ITD+ AML goes from Level 3A➡️1 w/ its U.S. FDA approval Quick poll: If you were to leave X where would you go to build up medTwitter??

It's out y'all! A new cBioPortal paper! Super grateful for the opportunity to follow in the footsteps of JJ Gao & Ethan Cerami! The article highlights work from tons of people to improve joint longitudinal genomic & clinical data analysis in cBioPortal!

Our new paper "Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer", is out in Cancer Discovery!

News about work in Cancer Discovery from Memorial Sloan Kettering Cancer Center: What Proportion of Cancer Patients May Benefit from Precision Oncology? More Than You Think! mskcc.org/clinical-updat…

Check out OncoKB™ 's new Precision Oncology Therapies page (oncokb.org/precision-onco…)! It's a great resource publically accessible on the OncoKB website, and here's why....

Join us at the #AMP2023 to meet the team and explore the latest developments @ booth#928 ! Our team members Hongxin Zhang and Ritika Kundra will answer all your licensing and content questions! #AMP2023 #OncoKB #PrecisionMedicine #MSKCC

New OncoKB data release v4.11

Packed house at #AMPath23 to see 🌟 lead scientist Debyani Chakravarty, PhD 🇺🇦 present OncoKB™, the U.S. FDA recognized cancer knowledge base, bringing precision oncology to patients at Memorial Sloan Kettering Cancer Center and now around the 🌏

New! Although #GenomicTests can lead to better outcomes in #CancerCare by informing #CancerRisk, prognosis, and therapeutic selection, they remain underutilized in routine #CancerCare. Find practical guidance from authors at acsjournals.onlinelibrary.wiley.com/doi/full/10.33… OncoAlert Melissa B Davis, PhD

It has been a year since my last update on the prospective MSK-IMPACT/ACCESS sequencing cohort, now >120,000 tumor/cfDNA samples analyzed. Thanks to the patients, docs, nurses, techs, data scientists who have contributed. So where are we going next:

New release my OncoKB™ people! Major updates: Removal of FGFR2-fusion+ #bladdercancer as L1 based on U.S. FDA amendmt to erdafitinib label +MDM2 amplification➡️L3A in intimal-& lipo-sarcomas based on compelling clinical activity of MDM2-p53 antag milademetan&brigimadlin resp

Through #GSoC, you will get a chance to work on cBioPortal OncoKB™ products. Join us!

New OncoKB data release v4.15: KRAS G12C Level 2 in amp cancer with sotorasib/adagrasib. Addition of new EGFR R2 resist. mts to osimertinib and Level 3A sensit. mts to afatinib. Removal of FGFR1 amp in LUSC based on limited response to FGFRi... and more, including 4 new genes!

New OncoKB data release v4.16: Release of CDx page incl biomarker, cancer type, drug & specimen type. BRAF fusions & V600 mts L1 in LGG. ERBB2 amp L2 in salivary gland cancer & L3A in solid tumors, the latter following FDA-approval of T-DXd for HER2+ (IHC3+) tumors + 7 new genes

Join us May 31-June 4 at the ASCO 2024 Annual meeting in Chicago at Booth # 37106 to meet our team, explore our latest developments and learn how you can use OncoKB in your research or clinical practice. We are here to answer any questions regarding OncoKB licensing and content!

New OncoKB data release v4.17: POLE/D1 exo dom mts and MSI-H L2 in CRC and SBC w/ pembro, nivo, ipi+nivo & dostar. MTAP del L3A in solid tumors w/ AMG193 & MRTX1719. ALK G1202R & L1196M L2 in NSCLC w/ lorl. Mobocertinib removal from L1 EGFR exon 20 in-frame ins in NSCLC & more!

New OncoKB data release v4.20 IDH1 R132 & IDH2 R172 L1 in astrocytoma & oligodendroglioma w/ Vorasidenib. Inavolisib L3A in PIK3CA onc mts in breast cancer. Removal of H3B-8800. CCNE1 amp, FBXW7 & PPP2R1A mts L3A in endo and ovarian cancer w/ Lunresertib+Camonsertib. And more!

Looking forward to #AMPath24 in November! Excited to meet colleagues and industry leaders, and share the latest from OncoKB. If you're attending, let's connect! #oncokb #precisiononcology

Excited to be heading to #AMPath24 soon! If you’re attending and want to talk about #OncoKB, let’s connect! I will be at our booth (#1421). Looking forward to it.

Agreed. The value of PR descriptions is often in things that are NOT directly inferable from the changes: - What original problem led to this PR? - Are there related issues / prior discussions? - What alternatives have been tried? Does this supersede previous attempts? - Why are